Eficacia de los inhibidores de la recaptación de la serotonina como tratamiento para los trastornos alimentarios.

Abstract

Background: Selective Serotonin Reuptake Inhibitors (SSRIs) are antidepressants used primarily to treat various mood and anxiety disorders. However, they are also used in the treatment of eating disorders such as anorexia nervosa and obesity. The effectiveness of SSRIs in this context is due to their ability to act on the root cause of these disorders, i.e., mood changes, thereby reducing the symptoms experienced by patients. SSRIs function by increasing the availability of serotonin in the brain—a neurotransmitter essential for regulating appetite, mood, and emotional control. Objective of the Study: To present the efficacy of selective serotonin reuptake inhibitors in the treatment of patients with eating disorders. Methods: The PRISMA 2020 guidelines were used, as their flowchart provides structured guidelines for conducting an accurate and organized systematic review. This is a descriptive and exploratory study. The research process involved searching the following databases: Scopus, SciELO, PubMed, DynaMed, Web of Science, and Taylor & Francis. Results: The efficacy of the main selective serotonin reuptake inhibitors—fluoxetine, citalopram, duloxetine, and paroxetine—will be evaluated in relation to the symptoms associated with eating disorders. Conclusion: The study will conclude based on the degree of efficacy shown by selective serotonin reuptake inhibitors in the treatment of eating disorders. Keywords: eating behavior disorders, eating disorders, neurotransmitter, cognitive behavioral therapy